For the present study, we analyzed a B-CLL population of 30 patients at different disease stage and characterized by different canonical clinical prognostic markers (CD38, IgHV status, chromosomal aberrations and TP53 mutations) (Table 1). The gene discussed is CD38; the disease is B-cell chronic lymphocytic leukemia.